Skip to main content

Table 3 Pooled relative risks of all-cause mortality for categorical and continuous analyses in subgroups

From: Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies

Sub-groups Triglyceride group (mg/dl) Per 1 mmol/L TG
<90 90-146 150-199 ≥200  
N* RR (95% CI) N* RR† N* RR (95% CI) N* RR (95% CI) N* RR (95% CI)
Age (year)
  <50 3 0.88 (0.78, 1.00) 5 1.00 5 1.14 (1.05, 1.24) 5 1.20 (0.99, 1.46) 8 1.13 (1.05, 1.21)
  ≥50 9 0.97 (0.85, 1.11) 9 1.00 9 1.07 (0.97, 1.18) 3 1.20 (0.97, 1.48) 14 1.12 (1.07, 1.17)
  P value   0.311     0.329   0.982   0.845
Gender
  Male 8 0.95 (0.84, 1.09) 9 1 9 1.12 (1.02, 1.22) 5 1.23 (1.09, 1.38) 14 1.09 (1.04, 1.13)
  Female 6 0.91 (0.84, 0.99) 6 1 6 1.17 (0.99, 1.39) 2 1.01 (0.59, 1.74) 10 1.24 (1.15, 1.32)
  Mixed 3 1.00 (0.85, 1.17) 4 1 4 1.11 (1.01, 1.21) 3 1.17 (1.01, 1.35) 6 1.08 (1.03, 1.13)
  P value   0.577     0.621   0.491   0.001
Follow-up (year)
  <15 6 0.89 (0.84, 0.94) 7 1.00 7 1.11 (0.97, 1.26) 4 1.26 (1.06, 1.51) 14 1.05 (1.02, 1.07)
  ≥15 6 0.94 (0.79, 1.11) 7 1.00 7 1.09 (1.02, 1.16) 4 1.15 (0.93, 1.41) 8 1.22 (1.16, 1.29)
  P value   0.569     0.773   0.490   0.000
Fast status
  Fast 8 1.01 (0.86, 1.20) 11 1.00 11 1.08 (0.98, 1.18) 5 1.27 (1.09, 1.48) 15 1.12 (1.06, 1.19)
  Nonfast 2 0.91 (0.86, 0.98) 3 1.00 3 1.14 (1.04, 1.24) 3 1.11 (0.88, 1.40) 6 1.11 (1.03, 1.19)
  Others§ 2 0.79 (0.63, 0.99) 2 1.00 2 1.11 (0.89, 1.38) 0 - 1 1.19 (1.09, 1.30)
  P value   0.258     0.381   0.335   0.740
Geographic location
  Europe/America 10 0.96 (0.87, 1.06) 11 1.00 11 1.09 (1.00,1.19) 6 1.19 (0.98, 1.45) 16 1.12 (1.06, 1.17)
  Asia-Pacific 2 0.81 (0.59, 1.11) 3 1.00 3 1.12 (1.02, 1.23) 2 1.22 (1.08, 1.39) 6 1.13 (1.08, 1.20)
  P value   0.302     0.633   0.813   0.640
Quality score
  <7 5 0.90 (0.86, 0.94) 7 1.00 7 1.15 (1.08, 1.24) 4 1.22 (1.07, 1.40) 10 1.13 (1.08, 1.18)
  7-9 7 0.95 (0.77, 1.17) 7 1.00 7 1.03 (0.91, 1.17) 4 1.19 (0.91, 1.57) 12 1.11 (1.05, 1.18)
  P value   0.594     0.116   0.869   0.707
Sample size
  <4000 7 0.97 (0.75, 1.25) 7 1.00 7 1.03 (0.92, 1.15) 4 1.22 (1.03, 1.45) 13 1.14 (1.07, 1.22)
  ≥4000 5 0.92 (0.86, 0.96) 7 1.00 7 1.14 (1.04, 1.24) 4 1.18 (0.95, 1.45) 9 1.09 (1.04, 1.14)
  P value   0.729     0.155   0.778   0.190
Free of CVDs at baseline
  Yes 5 0.94 (0.85, 1.03) 6 1.00 6 1.07 (0.99, 1.16) 5 1.24 (0.99, 1.56) 13 1.10 (1.04, 1.16)
  No 7 0.97 (0.80, 1.16) 8 1.00 8 1.10 (0.99, 1.23) 3 1.14 (1.00, 1.30) 9 1.13 (1.07, 1.20)
  P value   0.711     0.663   0.519   0.480
Adjustment
  Minimally 9 0.86 (0.72, 1.03) 10 1.00 10 1.14 (0.99, 1.30) 7 1.38 (1.13, 1.67) 8 1.12 (1.01, 1.24)
  Maximally 9 0.94 (0.80, 1.11) 10 1.00 10 1.07 (0.99, 1.17) 7 1.18 (1.01, 1.38) 8 1.07 (1.01, 1.13)
  P value   0.466     0.487   0.222   0.432
Adjustment for TC
  Yes 5 0.84 (0.7, 0.99) 5 1.00 5 1.03 (0.93, 1.14) 2 1.10 (0.88, 1.38) 11 1.10 (1.05, 1.15)
  No 7 1.00 (0.89, 1.12) 9 1.00 9 1.12 (1.02, 1.24) 8 1.27 (1.16, 1.40) 11 1.14 (1.07, 1.21)
  P value   0.103     0.225   0.239   0.382
Adjustment for HDL
  Yes 2 1.03 (0.93, 1.14) 2 1.00 2 1.02 (0.89, 1.17) 1 1.35 (1.09, 1.66) 4 1.07 (1.04, 1.11)
  No 10 0.92 (0.82, 1.02) 12 1.00 12 1.11 (1.03, 1.20) 8 1.14 (0.93, 1.39) 18 1.12 (1.07, 1.17)
  P value   0.115     0.296   0.250   0.132
  1. *The number of cohorts.
  2. †Reference group.
  3. §Others included mixed and unknown ones.
  4. RR, relative risk; CI, confidence interval; CVDs: cardiovascular diseases; HDL: high-density lipoprotein.
  5. TG: triglycerides; TC: total cholesterol.